Table of Content



1. Research Scope & Methodology
1.1. Study Objectives
1.2. Methodology
1.3. Assumptions & Limitations

2. Executive Summary
2.1. Market Size & Estimates
2.2. Country Snapshot
2.3. Country Analysis
2.4. Scope Of Study
2.5. Crisis Scenario Analysis
2.6. Major Market Findings
2.6.1. Increasing Collaboration Between Key Contract Manufacturers (Cmos)
2.6.2. Challenges In Navigating Complex Regulatory Requirements

3. Market Dynamics
3.1. Key Drivers
3.1.1. Rising Demand For Targeted Therapies
3.1.2. Growing Inclination Towards Contract Manufacturing Companies As An Economical Choice
3.1.3. Surging Global Cancer Incidence
3.1.4. Advancements In Drug Conjugation Technologies
3.2. Key Restraints
3.2.1. High Cost Of Adc (Antibody Drug Conjugates) Development And Manufacturing
3.2.2. Increasing Competition From Biosimilar Adc (Antibody Drug Conjugates) And Generic Drugs
3.2.3. Stringent Regulatory Requirements

4. Key Analytics
4.1. Key Market Trends
4.1.1. Rising Demand For Adcs
4.1.2. Growing Focus On Adc Quality And Regulatory Compliance
4.2. Pestle Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Legal
4.2.6. Environmental
4.3. Porter’S Five Forces Analysis
4.3.1. Buyers Power
4.3.2. Suppliers Power
4.3.3. Substitution
4.3.4. New Entrants
4.3.5. Industry Rivalry
4.4. Growth Prospect Mapping
4.4.1. Growth Prospect Mapping For United States
4.5. Market Concentration Analysis
4.6. Key Buying Criteria
4.6.1. Expertise And Experience
4.6.2. Manufacturing Capacity
4.6.3. Regulatory Compliance
4.6.4. Quality Control
4.6.5. Cost
4.7. Regulatory Framework

5. Market By Phase
5.1. Clinical Phase
5.1.1. Market Forecast Figure
5.1.2. Segment Analysis
5.2. Commercial Phase
5.2.1. Market Forecast Figure
5.2.2. Segment Analysis

6. Market By Linker
6.1. Cleavable Linkers
6.1.1. Market Forecast Figure
6.1.2. Segment Analysis
6.2. Non-Cleavable Linkers
6.2.1. Market Forecast Figure
6.2.2. Segment Analysis

7. Market By Condition
7.1. Myeloma
7.1.1. Market Forecast Figure
7.1.2. Segment Analysis
7.2. Lymphoma
7.2.1. Market Forecast Figure
7.2.2. Segment Analysis
7.3. Breast Cancer
7.3.1. Market Forecast Figure
7.3.2. Segment Analysis
7.4. Other Conditions
7.4.1. Market Forecast Figure
7.4.2. Segment Analysis

8. Competitive Landscape
8.1. Key Strategic Developments
8.1.1. Mergers & Acquisitions
8.1.2. Product Launches & Developments
8.1.3. Partnerships & Agreements
8.2. Company Profiles
8.2.1. Abbvie Inc (Abbvie Contract Manufacturing)
8.2.1.1. Company Overview
8.2.1.2. Services List
8.2.1.3. Strengths & Challenges
8.2.2. Cambrex Corporation
8.2.2.1. Company Overview
8.2.2.2. Services List
8.2.3. Catalent Inc
8.2.3.1. Company Overview
8.2.3.2. Services List
8.2.3.3. Strengths & Challenges
8.2.4. Merck Kgaa
8.2.4.1. Company Overview
8.2.4.2. Services List
8.2.4.3. Strengths & Challenges
8.2.5. Piramal Pharma Solutions
8.2.5.1. Company Overview
8.2.5.2. Services List
8.2.5.3. Strengths & Challenges



List of Figures

List Of Figures
Figure 1: Key Market Trends
Figure 2: Porter’S Five Forces Analysis
Figure 3: Growth Prospect Mapping For United States
Figure 4: Market Concentration Analysis
Figure 5: Key Buying Criteria
Figure 6: United States Antibody Drug Conjugates Contract Manufacturing Market, Growth Potential, By Phase, In 2023
Figure 7: United States Antibody Drug Conjugates Contract Manufacturing Market, By Clinical Phase, 2024-2032 (In $ Million)
Figure 8: United States Antibody Drug Conjugates Contract Manufacturing Market, By Commercial Phase, 2024-2032 (In $ Million)
Figure 9: United States Antibody Drug Conjugates Contract Manufacturing Market, Growth Potential, By Linker, In 2023
Figure 10: United States Antibody Drug Conjugates Contract Manufacturing Market, By Cleavable Linkers, 2024-2032 (In $ Million)
Figure 11: United States Antibody Drug Conjugates Contract Manufacturing Market, By Non-Cleavable Linkers, 2024-2032 (In $ Million)
Figure 12: United States Antibody Drug Conjugates Contract Manufacturing Market, Growth Potential, By Condition, In 2023
Figure 13: United States Antibody Drug Conjugates Contract Manufacturing Market, By Myeloma, 2024-2032 (In $ Million)
Figure 14: United States Antibody Drug Conjugates Contract Manufacturing Market, By Lymphoma, 2024-2032 (In $ Million)
Figure 15: United States Antibody Drug Conjugates Contract Manufacturing Market, By Breast Cancer, 2024-2032 (In $ Million)
Figure 16: United States Antibody Drug Conjugates Contract Manufacturing Market, By Other Conditions, 2024-2032 (In $ Million)

List of Tables

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT – ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY PHASE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 4: UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY PHASE, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 5: UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY LINKER, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 6: UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY LINKER, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 7: UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY CONDITION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 8: UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY CONDITION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 9: LIST OF MERGERS & ACQUISITIONS
TABLE 10: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 11: LIST OF PARTNERSHIPS & AGREEMENTS